Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of Eiger BioPharmaceuticals patents

List of Eiger BioPharmaceuticals patents

List of Suprema patents

List of Zume patents

List of Flex Logix patents

CEOs of computer companies

Companies in the Multimedia industry

Patents where

Current Assignee

Name

is

Eiger BioPharmaceuticals

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 11517532 Methods of treating hepatitis delta virus infection	Patent 11517532 was granted and assigned to Eiger BioPharmaceuticals on December, 2022 by the United States Patent and Trademark Office.	Eiger BioPharmaceuticals	Eiger BioPharmaceuticals		United States Patent and Trademark Office	11517532	December 6, 2022
	‌ US Patent 11571403 Methods for the treatment of non-alcoholic steatohepatitis	Patent 11571403 was granted and assigned to Eiger BioPharmaceuticals on February, 2023 by the United States Patent and Trademark Office.	Eiger BioPharmaceuticals	Eiger BioPharmaceuticals		United States Patent and Trademark Office	11571403	February 7, 2023
	‌ US Patent 11116820 Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives	Patent 11116820 was granted and assigned to Eiger BioPharmaceuticals on September, 2021 by the United States Patent and Trademark Office.	Eiger BioPharmaceuticals	Eiger BioPharmaceuticals		United States Patent and Trademark Office	11116820	September 14, 2021
	‌ US Patent 11311519 Treatment of hepatitis delta virus infection	Patent 11311519 was granted and assigned to Eiger BioPharmaceuticals on April, 2022 by the United States Patent and Trademark Office.	Eiger BioPharmaceuticals	Eiger BioPharmaceuticals		United States Patent and Trademark Office	11311519	April 26, 2022
	‌ US Patent 10076512 Treatment of hepatitis delta virus infection	Patent 10076512 was granted and assigned to Eiger BioPharmaceuticals on September, 2018 by the United States Patent and Trademark Office.	Eiger BioPharmaceuticals	Eiger BioPharmaceuticals		United States Patent and Trademark Office	10076512	September 18, 2018
	‌ US Patent 10653753 Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives	Patent 10653753 was granted and assigned to Eiger BioPharmaceuticals on May, 2020 by the United States Patent and Trademark Office.	Eiger BioPharmaceuticals	Eiger BioPharmaceuticals		United States Patent and Trademark Office	10653753	May 19, 2020
	‌ US Patent 10828283 Treatment of hepatitis delta virus infection	Patent 10828283 was granted and assigned to Eiger BioPharmaceuticals on November, 2020 by the United States Patent and Trademark Office.	Eiger BioPharmaceuticals	Eiger BioPharmaceuticals		United States Patent and Trademark Office	10828283	November 10, 2020
	‌ US Patent 10953072 Treatment of hepatitis delta virus infection with interferon lambda	Patent 10953072 was granted and assigned to Eiger BioPharmaceuticals on March, 2021 by the United States Patent and Trademark Office.	Eiger BioPharmaceuticals	Eiger BioPharmaceuticals		United States Patent and Trademark Office	10953072	March 23, 2021
	‌ US Patent 10588880 Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis	Patent 10588880 was granted and assigned to Eiger BioPharmaceuticals on March, 2020 by the United States Patent and Trademark Office.	Eiger BioPharmaceuticals	Eiger BioPharmaceuticals		United States Patent and Trademark Office	10588880	March 17, 2020

9 results

0 selected

9 results

0 selected